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In children, treatment regimen for high-grade gliomas (HGG) and diffuse intrinsic pontine gliomas (DIPG) are generally not stratified
according to disease stage. The hypothesis was that secondary disseminating disease (SDD) in children with HGG is related to an
even worse outcome. Description of SDD pattern was performed. In total, 270 children with newly diagnosed HGG or DIPG were
eligible for retrospective analysis of SDD. Medical and computer records of these patients were reviewed for demographic
characteristics, sites of dissemination, prognostic variables. Forty-six (17%) of the 270 patients had developed SDD. The median time
to SDD was 8.2 months. The median overall survival (OS) after dissemination was 3.2 months. The SDD was located parenchymal in
the supratentorial (34.8%), infratentorial (6.5%), supratentorial and infratentorial (19.6%), spinal (10.9%), spinal and cerebral (6.5%)
regions of the CNS, or leptomeningeal (21.7%). For HGG patients, the median OS was shorter among patients with SDD than
among patients without SDD (1.02 vs 1.41 years, P¼0.0495). In the group of patients with SDD, patients with cerebrospinal fluid
dissemination had a worse outcome compared with patients with parenchymal metastases. Summarising, SDD is a negative
prognostic factor for patients with HGG outside the pons. Treatment stratification should be considered.
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Tumours of the central nervous system (CNS) are the most
common solid neoplasms in children (Pollack, 1994). High-grade
gliomas (HGG) (World Health Organization grade III and IV)
constitute only 10–20% of childhood CNS tumours. In the German
Database for HGG, about 40% of children were registered with
diffuse intrinsic pontine glioma (DIPG). The diagnosis of DIPG is
performed by radiological criteria: larger than 50% of the pontine
diameter (Wagner et al, 2006) combined normally a short history
of disease. All other criteria are not suitable to distinguish between
focal and diffuse pontine glioma: DIPG includes tumours of WHO
grade I-IV histology showing contrast enhancement on magnetic
resonance imaging (MRI) and areas of necrosis and /or exophytic
components.
Owing to the small number of children with these neoplasms, it
is difficult to design and conduct prospective clinical trails of
treatments for HGG. In contrast to other childhood malignancies,
where treatment according to disease stage is standard, HGG
patients with metastases are treated the same way as patients with
localised disease. Owing to low incidences of secondary metastases
in HGG and DIPG there is no impact for alternative treatment
strategies.
In a previous study, we showed that about 3% of children with
HGG or DIPG initially present with disseminated tumour spread at
diagnosis so called primary dissemination of disease, stressing the
need for a complete initial diagnostic workup, including neuroaxis
MRI and cerebrospinal fluid (CSF) examination (Benesch et al,
2005). Most reports on tumour dissemination of HGG and DIPG
after diagnosis, so called secondary dissemination of disease
(SDD), are case reports or small series; few reports include large
numbers of patients (Packer et al, 1985, 1990, 1993; Dropcho et al,
1987; Vertosick and Selker, 1990; Grabb et al, 1992; Arita et al,
1994; Heideman et al, 1997; Donahue et al 1998; Allen et al, 1999;
Endo et al, 2003; Saito et al, 2003). These series mostly come from
the late 1980s and early 1990s, when MRI was not routinely
available for follow-up investigations (Awad et al, 1986; Vertosick
and Selker, 1990; Arita et al, 1994). Secondary disseminating
disease has been reported in 14–25% of adult patients with HGG
or DIPG. The percentage of paediatric patients with SDD varies
remarkably among studies (Table 1).
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sTable 1 Studies reporting on dissemination of high-grade gliomas
References (no) Histology (n)
Total
number of
patients
Site of
dissemi-
nation
%o f
SDD
Interval between primary
diagnosis and dissemination
median (range)
OS after diagnosis
of dissemination
median (range)
Treatment of
primary tumour
Treatment of
dissemination (n)
Arita et al, 1994 (5) GBM (10), AA (12) 157 ST BS, CB 14 20m (mean) (4–416 weeks) 6 mo (2–41 weeks) Surgery RT, CT ith-Ommaya-CT,
lumbal irradiation
Dropcho et al, 1987 (15) GBM (13), AA (29), malignant
glioma (8)
50 LM 26 7 months Surgery, CT, RT ith. interferon focal RT,
second surgery
Endo et al, 2003 (20) Cerebellar gliomas GBM (2),
AA (n¼2), anaplastic pilocytic
astrocytoma (n¼1)
5 LM 100 10 months (5–29) (2.8–4.8 mo) Surgery, local
RT+ACNU
Whole Brain RT+CT
(3) VP shunt MTX ith
Grabb et al, 1992 (14) GBM (4), mixed glioma (1),
Anaplastic oligodendroglioma
(3), AA (2), anaplastic
ependymoma (1)
33 LM, V 33 8 mo (1 w–59 months) 4 mo (3 w- 11 mo) Surgery, CT,
irradiation
Conventional CT ,no,
High-dose+BM rescue
(1) spinal
irradiation+CT (2)
Heideman et al, 1997 (16) GBM (n¼6), AA (n¼3) 29 LM, SP 31 3 y: 26% risk ND CSI ND
Packer et al, 1985 (17) AA (n¼34) 23 49 4 months ND ND
Saito et al, 2003 (22) AA, GBM 68 All 25 10.3 months (0–31.4) 8.6 months ND ND
17 SP 35 12.7 mo (7–35 mo) 5.6 months
Vertosick and Selker, 1990 (4) GBM 11 LM, SP 100 14.1 mo (5–62 mo) 2.8 months (2-7mo) ND ND
Donahue et al, 1998 (21) BS gliomas 18 LM 50 9 months (4–17 months) 9 months PFS
Allen et al, 1999 (23) BS gliomas 29 n.d. 44
Packer et al, 1990, 1993 (18,19) BS gliomas 35, 48 LM, LM 14, 8 ND ND ND ND
Current study GBM (20), AA 270 LM + 17 8.2 months 3.2 months Irradiation Relapse CT:
(17), GC-GBM V 98% topotecan,
temozolomide
(1), DIPG (8) SRCT:46% other CT;
Only pontine gliomas 110 13 7.2 months 3.6 months CT:91% RT, surgery: ND
Only nonpontine gliomas 146 22 8.2 months 3.1 months
AA, anaplastic astrocytoma; BM, bone marrow; BS, brainstem; CB, cerebellar; CSI, craniospinal irradiation; CT, chemotherapy; DD, disseminated disease; DIPG, diffuse intrinsic pontine glioma; GBM, glioblastoma multiforme; GC-
GBM, giant cell GBM; ith, intrathecal; LM, leptomeningeal; mo, months; nd, no data available; PFS, progression-free survival; RT, radiotherapy; SRCT, simultaneous radiochemotherapy (cisplatin; etoposide; ifosfamide; vincristine;
methotrexate); SP, spinal; ST, supratentorial; V, ventricular; VP, ventriculoperitoneal; w, weeks; y, year.
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sData of patients with HGG and DIPG included into this
retrospective study were recruited from a German HGG database
in which patients were registered since 1995 in a prospective series
of consecutive single-arm protocols using common diagnostic
criteria for eligibility, with overall survival (OS) as the primary end
point for comparison. The induction treatments consisted of
conformal normal-fractionated radiotherapy and chemotherapy
(Wolff et al, 2000, 2002a,b,c; Wagner et al, 2005), such as
trofosfamide and oral etoposide (Dropcho et al, 1987; Vertosick
and Selker, 1990); cisplatin, etoposide, ifosfamide (PEI) (Wolff
et al, 2002b); or PEI plus vincristine or PEI plus high-dose
methotrexate (Wagner et al, 2005). Data on metastatic disease were
included in baseline information, but they did not alter the
treatment strategies. In addition, all patients who developed
disease relapse or progression were offered treatment according
to the same protocol (Wagner et al, 2004). The most recent
protocol treatment for patients with relapsed disease differed for
those with completely vs incompletely resected recurrent disease,
but the presence of metastases did not alter these treatment
recommendations.
We performed a retrospective study in children with HGG or
DIPG to determine, whether SDD is related to a worse outcome.
Description of the pattern of SDD and the impact of SDD on OS
comparing HGG with DIPG was a secondary objective; in order to
obtain reliable data for treatment stratification in future studies.
MATERIALS AND METHODS
Only patients with reliable radiographic and/or histopathologic
evidence of SDD or non-SDD were included in this analysis.
Eligibility criteria included informed consent of parents or legal
guardians. Secondary disseminating disease was defined as the
unequivocal presence of SDD outside the area of the primary
tumour that had been documented by at least two different sources
of information (e.g., two follow-up MRI studies) or proven by
autopsy. Patients who were registered but who did not follow
treatment guidelines were not excluded. All computer records and
paper records were reviewed for diagnostic criteria of SDD by two
investigators (MB, SW). Referring hospitals were contacted for
missing data.
Treatment
Patients of this study were recruited of a database in which
patients were registered from July1995 until March 2005. Totally
653 patients were registered, and were enrolled into sequential
protocols (A–D) of the study for HGG and DIPG of the Paediatric
Oncology and Hematology Society of the German Language Group,
initiated by JW. All protocols were reviewed and approved by
Deutsche Krebsgesellschaft and the ethics committees of the
participating centres.
Treatment protocols A (1995–1997), B (1997–1999), C (1999–
2003) and D (has started 2003) have been previously described
(Wolff et al, 2000, 2002a; Wagner et al, 2005). In all protocols,
patients underwent conventional fractionated radiotherapy after
surgery with a total dose of 59.6 or 54.0Gy for children o6 years
old and for children with brainstem gliomas. The volume of tissue
irradiated was the tumour volume, as determined on preoperative
MRI, plus a 2-cm margin. One year chemotherapy in protocol A
consisted of oral trofosfamide (100mgm
 2 per day) and oral
etoposide (25mgm
 2perday) given once daily for 21 days,
repeated after 1 week of rest. In the following protocol (B),
patients underwent an intensive synchronous radiochemotherapy
regimen soon after surgery, consisting of two courses of induction
chemotherapy (cisplatin and etoposide in the first and cisplatin,
etoposide and ifosfamide in the second course). This synchronous
radiochemotherapy was also used for protocols C and D. In
protocol C, vincristine (1.5mgm
 2) was added once a week during
synchronous radiochemotherapy. In addition, six courses of PEI
were given as consolidation chemotherapy every 4 weeks after. In
protocol D, patients were either randomised to receive two doses
of high-dose methotrexate (5gm
 2) before induction radio-
chemotherapy or to immediately undergo induction radio-
chemotherapy. Consolidation therapy in this study consisted of
lomustine, vincristine and prednisone (every 6 weeks for eight
courses).
Response to treatment was defined as previously described
(Gnekow 1995; Wolff et al, 2000). Follow-up MRI was performed
every 3–6 months after radiochemotherapy according to protocol
guidelines and when the clinical course suggested disease
progression.
Diagnostic evaluation
The initial diagnostic evaluation for entering the study included
a complete physical and detailed neurological examination as well
as a brain MRI study with and without gadolinium. Spinal MRI
and cytologic examination of CSF were recommended but not
mandatory. Histopathologic diagnosis and grading of tumours
were performed by local neuropathologists according to the World
Health Organization classification of CNS tumours (Kleihues et al,
1993). Central neuropathologic review of the local pathological
diagnosis was performed in almost all patients at the Neuropatho-
logical Reference Centre at the University of Bonn in Germany.
The radiological diagnosis of a DIPG was reviewed by the
Neuroradiological Reference Centre in Wu ¨rzburg, Germany. The
criteria for DIPG were that the tumour had to be larger than 50%
of the pontine diameter. Criteria for HGG were a histopathological
diagnosis of a WHO1III or 1IV glioma. The extent of surgical
resection was documented using the neurosurgeon’s report and
postoperative contrast-enhanced MRI. Diagnosis of SDD was
based on MRI studies and was defined as evidence of linear or
nodular contrast-enhancing lesions outside the area of the primary
tumour on follow-up MRI studies.
Statistical analysis
Statistical analyses were performed using the commercially
available program SPSS version 12.0; SPSS Inc., Chicago, IL,
USA). The w
2-test was used to compare patient subgroups
concerning HGG, DIPG, SDD, age, gender, extent of resection.
The Kaplan–Meier method was used to estimate OS rates and
median OS time. The 95% confidence interval (CI) was defined by
the program as the 95% probability that the calculated OS time can
be found within this interval. Differences in OS were analysed with
the log-rank test and were estimated as relevant different with
a P-value of o0.05. Results were updated 30 April 2005.
RESULTS
Patient characteristics
During the period studied, 653 patients o21 years old with newly
diagnosed HGG or DIPG were registered into the above described
database. Of the 653 patients, 368 patients had HGG and 257 had
DIPG. We were not able to classify the remaining 28 patients
because of the lack of a reference radiological report and not
knowing the extent of the tumour. The eligibility criteria for this
study were met by 270 patients. Of these, 146 had HGG and 110
had DIPG. Fourteen patients could not be classified into either of
these groups because of a lack of clinical data. Forty-six (17%) of
the 270 patients developed SDD during the period studied. All
patients did not have metastases at primary diagnosis. The clinical
features of these patients are summarised in Table 2. The overall
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sincidence of SDD was 12.7% (14/110) for patients with DIPG, and
21.9% (32/146) for patients with HGG.
The median time between diagnosis of the primary tumour and
SDD was 8.2 months (range, 2.2 months–6.2 years) for the whole
group, 7.2 months (range, 4.6 months–2.2 years) for the DIPG
group, and 8.2 months (range, 2.2 months–6.2 years) for the HGG
group. In the majority of patients (n¼33; 71%), metastases
occurred soon after initial diagnosis (i.e., within 1 year). In six
patients (13%) metastases were observed between 1 and 2 years
after initial diagnosis, and in five patients (11%), metastases
occurred more than 2 years after diagnosis (no data available for 2
patients, 5%).
CSF examination was initially performed in 11 patients and was
positive in two of these patients. Metastases were found at various
combinations of anatomic sites in various combinations (Table 3).
Extra-CNS metastases were not found.
Primary treatment and response
The initial treatment that the 46 patients with SDD received is
presented in Table 2. The number of patients treated according to
protocols A–D was as follows: protocol A, n¼7 (15%); protocol B,
n¼11 (24%); protocol C, n¼20 (44%) and protocol D, n¼8
(17%). Eight weeks after the initiation of therapy, response was
Table 2 Clinical characteristics of patients with secondary metastases (n¼46) and without SDD (n¼224)
Patients with SDD Patients without SDD
Characteristics n % n %
Gender
Male 27 58.7 115 51.3
Female 19 41.3 109 48.7
Median age at primary diagnosis 10.2 years (0.1–19.1 years) 9.2 years (0.1–21 years)
Primary tumour site
Cerebral hemispheres 14 30.4 53 23.7
Pons/brainstem 14 30.4 106 47.3
Thalamus/basal ganglia 6 13.0 24 10.7
Cerebellum 5 10.9 5 2.2
Ventricles 2 4.3 6 2.7
Medulla 1 2.2 1 0.4
Pineal region 1 2.2 1 0.4
Hypothalamus 0 0 2 0.9
Spinal cord 1 2.2 4 1.8
Gliomatosis cerebri 2 4.3 11 4.9
Brain NOS 0 0 11 4.9
Diagnosis
Glioblastoma multiforme grade IV 20 43.5 76 33.9
Giant cell glioblastoma grade IV 1 2.2 2 0.9
Anaplastic astrocytoma grade III 17 37.0 63 28.1
Oligoastrocytoma/-dendroglioma grade III 0 0 5 22.3
Gliosarcoma grade IV 0 0 2 0.9
Astroblastoma/xantoastrocytoma grade III 0 0 3 1.3
Astrocytoma WHO grade I/II (DIPG) 2 4.3 16 7.1
DIPG, only radiologic diagnosis 6 13.0 57 25.4
Spinal MRI at primary diagnosis 10/39* 25.6 nd
CSF positive at primary diagnosis 2/11* 18.2 3/33 9.1
Resection of the primary tumour (n¼222)
Complete resection 7 15.2 33 14.9
Subtotal resection (X95% of the tumor removed) 9 19.6 24 10.8
Partial resection (o 95% of the tumor removed) 9 19.6 39 17.7
Biopsy 15 32.6 75 33.8
No surgery 6 13.0 51 22.9
Irradiation of the primary tumour (n¼221)
Yes 45 97.8 201 90.9
No 1 2.2 20 9.1
Simultaneous radiochemotherapy of the primary tumor (n¼220)
Yes 21 45.7 95 43.2
No 25 54.3 125 56.8
Chemotherapy of the primary tumour (n¼221)
Yes 42 91.3 204 92.3
No 4 8.7 17 7.7
MRI¼magnet resonance imaging; CSF¼cerebrospinal fluid; DIPG¼diffuse intrinsic pontine glioma; NOS¼no other specification.*Data were available for only 39 or 11
patients.
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sevaluated in the 36 patients before the onset of SDD without a
complete tumour resection (Table 4), revealing a complete
remission in two patients (6%), partial remission in six patients
(17%), stable disease in 20 patients (56%) and progressive disease
in eight patients (22%). Six of the seven patients who had complete
tumour resections were in continuous complete remission at the
time of the first response evaluation. Data on remission status were
not available for three patients.
Data on the systemic treatment of patients with SDD were
available for only 30 patients because this was no further a
protocol question in the A–D protocol (Table 3). Unfortunately,
data on second surgeries were not uniformly reported.
OS of patients with and without SDD
Evaluation of all 270 patients for whom SDD data were available
did not reveal any difference in OS between patients with and
without SDD. The median OS was 1.0270.14 years (95% CI, 0.75–
1.30 years) for patients with SDD and 1.0170.06 years (95% CI,
0.90–1.12 years) (P¼0.473) for patients without SDD. For the
patients with HGG, we found a survival difference between patients
with and without SDD. The median OS of HGG patients with SDD
(n¼32) was 1.0270.21 years (95% CI, 0.61–1.43 years), and the
median OS of HGG patients without SDD (n¼14) was 1.4170.28
years (95% CI, 0.86–1.95 years) (P¼0.0495). In contrast, in the
subgroup of patients with DIPG, no differences in median OS were
found between patients with and without SDD.
Further analyses of HGG patients revealed a difference in
median OS between patients with (n¼15; median OS¼0.8670.2
years; 95% CI, 0.46–1.25 years) and without (n¼42; 2.2870.95
years; 95% CI, 0.42–4.15 years) SDD among those with grade III
tumours (P¼0.001, Figure 1A) but not among those with grade IV
tumours (Figure 1B). Similarly, a difference in OS between HGG
patients with (n¼20; median OS¼0.7970.10 years; 95% CI,
0.59–0.99 years) and without (n¼73; median OS¼1.3770.15
years; 95 % CI, 0.8–1.66 years; P¼0.023) SDD was found in
younger children (o 13 years) but not in older children (X13
years).
Overall survival was longer for patients with parenchymal
metastases (n¼22; median OS for patients without leptomenin-
geal/ventricular SDD¼1.1870.19 years; 95% CI, 0.80–1.56 years)
compared with patients whose tumours had spread through the
CSF (n¼22; median OS of patients with leptomeningeal/ventri-
cular SDD¼0.7270.05 years; 95% CI, 0.62-0.81 years) (P¼0.049)
(Figure 2). For patients with SDD, the median OS after SDD was
0.2770.05 years (n¼44, 95% CI, 0.18–0.37 years) for the HGG
and DIPG groups combined. No patient survived longer than 1.8
years after the diagnosis of SDD; the 1-year OS rate after being
diagnosed with SDD was 16.776.1%. A statistically significant
difference in OS was found when the different sites of the
intracranial metastases were compared.
DISCUSSION
This is the largest survey on SDD in paediatric HGG and DIPG
patients to date. As expected, the majority (72%) of cases of SDD
were detected soon after initial diagnosis (within 1 year). However,
there was an interesting small group of five patients who developed
SDD more than 2 years after diagnosis, indicating that the
biological characteristics of HGG and DIPG tumours are more
complex than anticipated.
In our study, SDD did influence OS in patients with HGG,
as they had a shorter OS than those without SDD. However,
SDD had little impact on the OS of the HGG and DIPG groups
combined. Secondary disseminating disease did not reduce OS
in the DIPG group, suggesting that rapid local tumour progression
was the main cause of the short OS in these patients and that
SDD had no additional effect. We conclude, therefore, that in DIPG
Table 3 Characteristics of secondary dissemination
Number of patients (%)
Characteristics Whole group HGG DIPG
Median time from primary diagnosis to secondary dissemination 8.2 months 8.2 months 7.2 months
Parenchymal metastasis (n¼46) (n¼32) (n¼14)
Supratentorial 16 (34.8%) 11 (34.4%) 5 (35.7%)
Supra-+infratentorial 9 (19.6%) 6 (18.8%) 3 (21.4%)
Infratentorial 3 (6.5%) 2 (6.3%) 1 (7.1%)
Spinal 5 (10.9%) 4 (12.5%) 1 (7.1%)
Cerebral+spinal 3 (6.5%) 0 3 (21.4%)
Leptomeningeal dissemination 10 (21.7%) 9 (28.1%) 1 (7.1%)
Chemotherapy of disseminated disease (n¼30) (n¼22) (n¼8)
Topotecan 7 (23.3%) 4 (18.2%) 3 (38%)
Temozolomide 11 (36.7%) 9 (40.9%) 2 (25%)
Valproic acid 1 (3.3%) 1 (4.5%) 0 (0%)
Other chemotherapy 9 (30.0%) 6 (27.3% 3 (38%)
No chemotherapy 2 (6.7%) 2 (9.1% 0 ((0%)
Irradiation of disseminated disease 22 0
Second surgery of disseminated disease ND ND ND
No treatment of disseminated disease 22 0
Median OS after diagnosis of secondary dissemination (months) 3.2 3.1 3.6
ND¼no data available; DIPG¼diffuse intrinsic pontine gliomas; HGG¼high-grade gliomas; OS¼overall survival.
Table 4 Comparison of response in HGG and DIPG patients with and
without secondary dissemination 8 weeks after primary treatment
Response to primary treatment Before SDD Without SDD
CCR 6/7* 14.3% 22/33 11%
Response (complete and partial)
a 8/36 22.3% 37/170 21.7%
Stable disease
a 20/36 55.6% 84/170 49.4%
Progressive disease
a 8/36 22.3% 49/170 28.8%
CCR¼continuous complete remission after complete resection; DIPG¼diffuse
intrinsic pontine gliomas; HGG¼high-grade gliomas; SDD¼secondary disseminating
disease. *Six of seven patients available for this analysis.
aIn patients without complete
tumour resection.
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spatients, treatment should primarily focus on controlling local
disease.
Among patients with HGG, OS was shorter in patients with SDD
in grade III tumours and with age of o13 years. We suggest that
HGG patients in these subgroups might benefit from an intensive
treatment of metastases, such as spinal or local irradiation or
surgery, since tumour progression at the primary site seems to
occur less rapidly compared to patients with DIPG.
The overall incidence of SDD in our study was 17% (HGG, 22%;
DIPG, 13%), which is in the lower part of the range reported by
others (Table 1, Dropcho et al, 1987). The highly variable incidence
rates of SDD in these other studies might be explained by the fact
that they were single-centre-based studies with a limited number
of patients, or that they had incomplete CNS staging and different
MRI surveillance strategies. In addition, treatment intensity,
including high-dose chemotherapy, and post-mortem examina-
tions might have had some impact on the proportion of patients
with HGG or DIPG who were diagnosed with SDD in those studies
(Table 1). Treatment intensity, in particular, might alter the
metastatic potential of HGG and DIPG, thereby affecting the OS in
patients with these diseases. Normally data on SDD in HGG or
DIPG patients were seldom available because the patients had a
short OS, so dissemination did not have time to occur.
Interestingly, in HGG and DIPG patients, dissemination to
leptomeningeal and ventricular tumour sites resulted in shorter OS
compared with parenchymal metastases; this observation could
redirect new treatment approaches. One of these new approaches
could be intrathecal administration of chemotherapeutic drugs as
it was proposed by Donahue et al (1998).
Before initiating new treatment approaches, however, better
diagnostic standards, such as craniospinal MRI and mandatory
CSF examination, must be implemented in addition to more
sensitive methods for screening CSF. Risk factor analysis (e.g.,
genetic factors to predict SDD in HGG) is another important issue
to be addressed in future studies. Even if this retrospective study is
the largest survey of patients with SDD, patient numbers are still
small. In order to get more experiences with SDD in the group of
HGG and DIPG, new protocols should at least plan prospective
detailed documentation of SDD. For the first time it was reported
that SDD is as a negative prognostic factor in HGG. This finding
should still be confirmed by other studies, however, it does suggest
a biological relevance of secondary metastases in high-grade
glioma, and leads to reconsider intrathecal therapy for these
tumours in children.
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patients (A) and grade IV patients (B) with and without SDD.
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Figure 2 Kaplan–Meier curves for OS of HGG and DIPG patients with
secondary disseminated disease with and without leptomenigeal (LM)/
ventricular dissemination.
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